MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Operating Income 2011-2026 | VIVO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.4 M | 93 M | 61.3 M | 32.7 M | 31.6 M | 37.4 M | 51.4 M | 56.1 M | 52.4 M | 57.3 M | 49.3 M | 40 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93 M | 31.6 M | 51.4 M |
Quarterly Operating Income Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.1 M | - | - | 36.1 M | 20.3 M | - | 15.7 M | 34.2 M | 34.7 M | 51.8 M | 34.7 M | 34.7 M | 5.39 M | 26.8 M | 6.46 M | 5.39 M | 10.6 M | 24.5 M | 8.74 M | 10.6 M | 8.06 M | 28.6 M | 4.3 M | 8.06 M | 10.1 M | 42.5 M | 13.7 M | 10.1 M | 13.6 M | 42.8 M | 14.4 M | 13.6 M | 12.7 M | 40.4 M | 13.1 M | 12.7 M | 11.6 M | 44 M | 15.7 M | 11.6 M | 13.1 M | 37.2 M | 12.6 M | 13.1 M | 9.8 M | 30.2 M | 10.1 M | 9.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.8 M | -28.1 M | 18.7 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.35 B | $ 115.35 | -2.33 % | $ 35.1 B |  USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.81 | -2.7 % | $ 91.2 K | USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 12.28 | -2.69 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 22.48 | -1.58 % | $ 234 M |  China |
 |
Bioventus
BVS
|
54 M | $ 8.45 | -7.14 % | $ 563 M | USA |
 |
Celcuity
CELC
|
-113 M | $ 114.85 | -0.34 % | $ 4.53 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 27.23 | -2.44 % | $ 756 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 175.23 | -3.37 % | $ 8.69 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.59 | 2.41 % | $ 441 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
|
Biodesix
BDSX
|
-34.5 M | $ 18.61 | 17.37 % | $ 2.41 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 124.76 | -2.71 % | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 175.33 | -1.8 % | $ 30.1 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.11 | -1.36 % | $ 1.41 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 199.8 | -2.07 % | $ 22.2 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 195.75 | -2.99 % | $ 140 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 607.19 | -1.9 % | $ 48.8 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.5 | 0.17 % | $ 19.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 9.69 | -3.0 % | $ 275 M | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 269.52 | -2.34 % | $ 22.4 B | USA |
 |
DexCom
DXCM
|
912 M | $ 68.5 | -3.1 % | $ 26.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 107.08 | -3.19 % | $ 8.83 B |  Irlanda |
 |
Lantheus Holdings
LNTH
|
311 M | $ 72.86 | -4.53 % | $ 4.92 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.91 | -4.48 % | $ 954 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 5.15 | 0.29 % | $ 477 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.92 | -2.3 % | $ 1.14 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 14.48 | 3.13 % | $ 324 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 91.56 | -1.1 % | $ 11.5 B | USA |
 |
Natera
NTRA
|
-541 M | $ 196.94 | -0.1 % | $ 19.4 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
OPKO Health
OPK
|
-152 M | $ 1.18 | 0.43 % | $ 819 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |